U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07275606) titled 'A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1' on Nov. 27.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
Study Start Date: March 17, 2026
Study Type: INTERVENTIONAL
Condition:
HIV Infections
Intervention:
DRUG: Oral CAB
CAB administered once orally on study Day 1 to the Stage 1: Single Oral Dose CAB (Cohort 1) and multiple times to the Stage 1: Multiple Oral Dose CAB (Cohort 2) group. Dose and dosing frequency for Cohort 2 to be determined based on emerging data from Coh...